Loading…
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-28M | $-27M | $-28M | -37.9% | - | -13.0% |
| 2024 | $0M | $-32M | $-31M | $-35M | -326.3% | - | -17.3% |
| 2023 | $0M | $-38M | $-37M | $-37M | 468.2% | -100.0% | -9.6% |
| 2022 | $1M | $-32M | $-41M | $-28M | -851.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1 | 0 | 0 | 0 |
| Operating Revenue | - | 1 | 0 | 0 | 0 |
| Cost Of Revenue | 0.20 | 0.10 | 0 | - | - |
| Gross Profit | 7.40 | 0.90 | 0 | - | - |
| Operating Expense | - | 32.85 | 37.87 | 31.51 | 28.27 |
| Research And Development | - | 20.27 | 24.01 | 19.10 | 16.02 |
| Selling General And Administration | - | 12.58 | 13.86 | 12.42 | 12.25 |
| Total Expenses | - | 32.95 | 37.87 | 31.51 | 28.27 |
| Operating Income | - | -31.95 | -37.87 | -31.51 | -28.27 |
| Total Operating Income As Reported | - | -41.95 | -37.87 | -31.51 | -28.27 |
| EBITDA | - | -31.95 | -37.87 | -31.51 | -28.27 |
| Normalized EBITDA | - | -22.28 | -37.87 | -31.51 | -28.27 |
| EBIT | - | -31.95 | -37.87 | -31.51 | -28.27 |
| Interest Income | - | 0.32 | 0.52 | 0.63 | 1.41 |
| Net Interest Income | - | 0.32 | 0.52 | 0.63 | 1.41 |
| Other Income Expense | -1.35 | -9.67 | 0 | - | - |
| Interest Income Non Operating | - | 0.32 | 0.52 | 0.63 | 1.41 |
| Net Non Operating Interest Income Expense | - | 0.32 | 0.52 | 0.63 | 1.41 |
| Pretax Income | - | -41.30 | -37.34 | -30.88 | -26.86 |
| Tax Provision | -0.24 | 0 | - | - | - |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -41.30 | -37.34 | -30.88 | -26.86 |
| Net Income From Continuing And Discontinued Operation | - | -41.30 | -37.34 | -30.88 | -26.86 |
| Net Income From Continuing Operation Net Minority Interest | - | -41.30 | -37.34 | -30.88 | -26.86 |
| Net Income | - | -41.30 | -37.34 | -30.88 | -26.86 |
| Net Income Common Stockholders | - | -41.30 | -37.34 | -30.88 | -26.86 |
| Net Income Including Noncontrolling Interests | - | -41.30 | -37.34 | -30.88 | -26.86 |
| Normalized Income | - | -31.63 | -37.34 | -30.88 | -26.86 |
| Diluted NI Availto Com Stockholders | - | -41.30 | -37.34 | -30.88 | -26.86 |
| Basic Average Shares | - | 19.40 | 27.78 | 61.20 | 109.05 |
| Diluted Average Shares | - | 19.40 | 27.78 | 61.20 | 109.05 |
| Reconciled Cost Of Revenue | 0.20 | 0.10 | 0 | - | - |
| Total Unusual Items | -1.35 | -9.67 | 0 | - | - |
| Total Unusual Items Excluding Goodwill | -1.35 | -9.67 | 0 | - | - |
| Special Income Charges | -1.36 | -9.70 | 0 | - | - |
| Other Special Charges | - | 10 | - | - | - |
| Impairment Of Capital Assets | 5.70 | 0 | - | - | - |
| Restructuring And Mergern Acquisition | -4.34 | -0.30 | 0 | - | - |
| Gain On Sale Of Security | 0.02 | 0.04 | 0 | - | - |
| General And Administrative Expense | - | 12.58 | 13.86 | 12.42 | 12.25 |
| Other Gand A | - | 12.58 | 13.86 | 12.42 | 12.25 |
| Otherunder Preferred Stock Dividend | 0 | - | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| SELLAS Life Sciences Group, Inc.this co. | SLS | $1.8B | -66.17 | 25.08 | -37.9% | -60.37 |
| Pediatrix Medical Group, Inc. | MD | $1.8B | 11.11 | 2.12 | 19.1% | 7.64 |
| Viridian Therapeutics, Inc. | VRDN | $1.8B | -5.34 | 3.10 | -58.1% | -4.95 |
| Vericel Corporation | VCEL | $1.8B | 110.33 | 5.14 | 4.7% | 60.29 |
| ANI Pharmaceuticals, Inc. | ANIP |
| - |
| - |
| - |
| - |
| - |
| - |
| $1.8B |
| 22.99 |
| 3.33 |
| 14.5% |
| 10.29 |
| Nuvation Bio Inc. | NUVB | $1.8B | -8.80 | 5.89 | -66.9% | -8.95 |
| Rapport Therapeutics, Inc. | RAPP | $1.8B | - | -178.20 | -23.0% | - |
| Surgery Partners, Inc. | SGRY | $1.8B | -22.97 | 1.04 | -4.5% | 9.86 |
| UFP Technologies, Inc. | UFPT | $1.7B | 25.43 | 4.10 | 16.1% | 16.79 |
| Peer Median | - | 11.11 | 3.22 | 0.1% | 9.86 | |